common drugs use in common drugs use in ophthalmology
play

Common Drugs Use in Common Drugs Use in Ophthalmology Ophthalmology Rungroj Lertvithayasakul, MD Rungroj Lertvithayasakul, MD Varintorn Chuckpaiwong, MD Varintorn Chuckpaiwong, MD Department of Ophthalmology, Ramathibodi Hospital Department

0 downloads 1 Views 2 MB Size Report
  1. Common Drugs Use in Common Drugs Use in Ophthalmology Ophthalmology Rungroj Lertvithayasakul, MD Rungroj Lertvithayasakul, MD Varintorn Chuckpaiwong, MD Varintorn Chuckpaiwong, MD Department of Ophthalmology, Ramathibodi Hospital Department of Ophthalmology, Ramathibodi Hospital School of Medicine, Mahidol University School of Medicine, Mahidol University , , y y

  2. Route of Administration Route of Administration Route of Administration Route of Administration � Local Local • Topical Topical • Intravitreous Intravitreous • Subconjunctival Subconjunctival • Subtenon Subtenon • Retrobulbar Retrobulbar • Intracameral Intracameral � Systemic Systemic y Blood aqueous barrier Blood aqueous barrier Blood retinal barrier Blood retinal barrier Blood retinal barrier Blood retinal barrier

  3. Eyedrops Eyedrops Eyedrops Eyedrops 50 µl per drop • Only Only 20 20 % of the administered % of the administered drugs is retained drugs is retained • One drop is enough. One drop is enough. p p g g Volume of fluid held by cul-de-sac 7 – 10 µl

  4. Drug eliminating mechanisms Drug eliminating mechanisms Drug eliminating mechanisms Drug eliminating mechanisms Lacrimal gland Lacrimal gland Tear production: Tear production: 1 1. .2 2 µl /min µl /min Turn over rate 16 % per min Remaining 4 min : 50 % 10 min : 17 % Nasal cavity Nasal cavity Nasal cavity Nasal cavity cm 2 Surface area of Surface area of 150 150 - - 200 200 cm ( ( 13 13 times of conjunctiva ) times of conjunctiva ) 200 200 times of cornea times of cornea

  5. Drug eliminating mechanisms Drug eliminating mechanisms Drug eliminating mechanisms Drug eliminating mechanisms If the drug is If the drug is Dilution of drug Dilution of drug irritating to the eye irritating to the eye tat g to t e eye tat g to t e eye O e Overflow drainage O e Overflow drainage o o d a age d a age

  6. Improve ocular and decrease systemic Improve ocular and decrease systemic absorption absorption � Digital pressure at medial canthal Digital pressure at medial canthal area area � Keep eyes closed for Keep eyes closed for 5 p p y y 5 min after min after taking drops taking drops � Wait Wait 10 W it W it 10 10 10 minutes between drops minutes between drops i i t t b t b t d d � Frequency ~ duration of action Frequency ~ duration of action � Order of using ~ pH Order of using ~ pH

  7. Drug Penetration Drug Penetration Precorneal area Precorneal area Cornea Cornea Anterior Segment Anterior Segment Aqueous Humor Aqueous Humor

  8. Drug Penetration Drug Penetration Drug Penetration Drug Penetration Factors that determine the amount of medication Factors that determine the amount of medication to penetrate the cornea to penetrate the cornea • Drug concentration Drug concentration • Viscosity • Viscosity Viscosity Viscosity • Lipid/water solubility Lipid/water solubility • pH pH H • Surfactants Surfactants • Reflex tearing Reflex tearing • Preservative Preservative

  9. Form Form Form Form � Solution and suspension Solution and suspension � Ointment Oi t Oi t Ointment t t � Gel Gel

  10. Solution and Suspension Solution and Suspension Solution and Suspension Solution and Suspension Most commonly used Most commonly used y Advantages Advantages - Easily instilled Easily instilled Easily instilled Easily instilled - Less interfere to vision Less interfere to vision - Fewer potential complications Fewer potential complications Fewer potential complications Fewer potential complications Disadvantages Disadvantages Disadvantages Disadvantages - Short ocular contact time Short ocular contact time - Imprecise and inconsistent delivery Imprecise and inconsistent delivery Imprecise and inconsistent delivery Imprecise and inconsistent delivery - Frequent contamination Frequent contamination - Possibilities of ocular injury with the dropper tip P Possibilities of ocular injury with the dropper tip P ibiliti ibiliti f f l l i j i j ith th ith th d d ti ti

  11. Suspensions Suspensions Suspensions Suspensions Must be re Must be re- -suspended by shaking to provide suspended by shaking to provide an accurate dosage of drug an accurate dosage of drug g g g g

  12. Ointment Ointment Ointment Ointment � Consist of petrolatum and mineral oil Consist of petrolatum and mineral oil � Increase contact time � Increase contact time Increase contact time Increase contact time � Disturb vision Disturb vision

  13. Gel Gel Gel Gel � Polymer Polymer- -based aqueous gels based aqueous gels � Drug release occurs by diffusion and by erosion Drug release occurs by diffusion and by erosion of the gel surface of the gel surface f th f th l l f f

  14. Techniques of Instillation Techniques of Instillation Techniques of Instillation Techniques of Instillation Eye ointment Eye drop Eye ointment

  15. Packaging Packaging Packaging Packaging The outer surface The outer surface dimensions of the tip dimensions of the tip affects drop size affects drop size p

  16. Packaging Packaging Packaging Packaging Standard colors for drug labeling and bottle cap Standard colors for drug labeling and bottle cap g g g g p p Yellow Yellow, Yellow Yellow Blue , Blue Blue Blue B blocker B blocker B blocker B blocker Red Red Mydriatics and cycloplegics Mydriatics and cycloplegics Green Green Miotics Miotics Orange Orange Carbonic anhydrase inhibitors Carbonic anhydrase inhibitors Brown or tan Brown or tan Anti Anti- -infective agents infective agents Gray Gray Gray Gray NSAIDS NSAIDS NSAIDS NSAIDS Pink Pink Steroids Steroids

  17. Commonly used drugs Commonly used drugs

  18. Anesthesia Anesthesia Anesthesia Anesthesia Topical T Topical T i i l l � Cornea, conjunctiva Cornea, conjunctiva � Irritate Irritate 15 15 sec sec � Duration Duration 15 15 min min � For FB removal, IOP measurement, etc. For FB removal, IOP measurement, etc. � Complications : toxic to epithelium � Complications : toxic to epithelium Complications : toxic to epithelium Complications : toxic to epithelium Tetracaine hydrochloride (Tetracaine) 0.5% Tetracaine hydrochloride (Tetracaine) Tetracaine hydrochloride (Tetracaine) Tetracaine hydrochloride (Tetracaine) 0 5% Benoxinate hydrochloride (Novesine) Benoxinate hydrochloride (Novesine) 0. .4 4% %

  19. Anesthesia Anesthesia Anesthesia Anesthesia Local Local � Including akinesia Including akinesia g � For surgery For surgery � Complications: overdose, systemic absorption Complications: overdose systemic absorption Complications: overdose systemic absorption Complications: overdose, systemic absorption (respiratory distress, seizure) (respiratory distress, seizure) Lidocaine hydrochloride (Xylocaine) Lidocaine hydrochloride (Xylocaine) 1- -2 2 % % 1 1- -2 2 hr hr Bupivacaine hydrochloride (Marcaine) Bupivacaine hydrochloride (Marcaine) 0. .25 25- -0 0. .5 5% % 5- -7 7 hr hr

  20. Mydriatics Mydriatics y I. Sympathomimetics I. Sympathomimetics � Stimulate dilator muscle Stimulate dilator muscle � Complications: AACG, vasoconstriction Complications: AACG, vasoconstriction � For retinal examination, surgery For retinal examination surgery For retinal examination surgery For retinal examination, surgery Phenylephrine hydrochloride (Neosynephrine) Phenylephrine hydrochloride (Neosynephrine) 10 10% % 2 2- -3 3 hr hr

  21. Mydriatics Mydriatics Mydriatics Mydriatics II Parasympatholytics / Cycloplegics II Parasympatholytics / Cycloplegics II. Parasympatholytics / Cycloplegics II. Parasympatholytics / Cycloplegics � Inhibit constrictor m.and ciliary m. contraction Inhibit constrictor m.and ciliary m. contraction � Complications: AACG, flushing Complications: AACG, flushing � For ciliary spasm, refraction in children, retinal For ciliary spasm, refraction in children, retinal y p y p exam exam Atropine sulfate 1% Atropine sulfate % 2 2 wk wk Scopolamine hydrobromide Scopolamine hydrobromide 0. p p y y .25 25% % 3 3- -5 5 d Homatropine hydrobromide Homatropine hydrobromide 1- -2 2% % 1 1- -3 3 d Cyclopentolate hydrochloride (Cyclogyl) Cyclopentolate hydrochloride (Cyclogyl) 1% y y p p y y ( y ( y gy ) gy ) % % 24 24 hr hr Tropicamide (Mydriacyl) Tropicamide (Mydriacyl) 0. .5 5- -1 1% % 4 4- -5 5 hr hr

  22. Mydriatics and Cycloplegics Mydriatics and Cycloplegics � Atropine sulfate At At Atropine sulfate i i lf t lf t � Cyclopentolate HCl Cyclopentolate HCl Cyclopentolate HCl Cyclopentolate HCl � Tropicamide � Tropicamide Tropicamide Tropicamide � Phenylephrine HCl Phenylephrine HCl y p y p

  23. ผปวยชายอาย 40 ป ตาขวาเคืองเจ็บ มานาน 1 วัน ผูปวยชายอายุ 40 ป ตาขวาเคองเจบ มานาน 1 วน การวินิจฉัยโรค ิ ิ ั โ การรักษา

  24. ิ ั ผูปวยหญิงอายุ 45 ป ปวดตาขวา ตาแดง มีขีตา ป ป ป ี ี้ มานาน 3 วัน มานาน 3 วน การวินิจฉัยโรค การวนจฉยโรค การรกษา

  25. Antibiotics Antibiotics Antibiotics Antibiotics

Recommend Documents


drugs
Drugs H O W T O K E E P O U R B O

Just Say No! to Drugs H O W T O K E E P O U R B O D I E S H E A L T H Y

drugs
Drugs H O W T O K E E P O U R B O

Just Say No! to Drugs H O W T O K E E P O U R B O D I E S H E A L T H Y

the nervous system and drugs
The Nervous System and Drugs How drugs

The Nervous System and Drugs How drugs affect the nervous system Adapted from

new drugs in aml
New Drugs in AML New version of old

New Drugs in AML New version of old drugs Inhibitors of signaling pathways

wiltshire
WILTSHIRE Drugs and Alcohol Strategy

WILTSHIRE Drugs and Alcohol Strategy 2019-2022 Reducing harm caused by drugs

the drugs don t work
The Drugs Dont Work Federica Dal Bello

The Drugs Dont Work Federica Dal Bello In the last decades the abuse of drugs

drugs in workplace problem
Drugs in Workplace Problem? 70% of

Drugs in Workplace Problem? 70% of estimated users of illegal drugs are

protein drugs
PROTEIN DRUGS PEPTIDE AND PROTEIN

Pharmacokinetics of PROTEIN DRUGS PEPTIDE AND PROTEIN DRUGS In this

detection and identification of illicit drugs and cutting
Detection and Identification of Illicit

Detection and Identification of Illicit Drugs and Cutting Agents in Seized

newer drugs for myelofibrosis
Newer Drugs for Myelofibrosis Giovanni

Newer Drugs for Myelofibrosis Giovanni Barosi Center for the Study of

clinical presentation of glaucoma
CLINICAL PRESENTATION OF GLAUCOMA

CLINICAL PRESENTATION OF GLAUCOMA DR.FAISAL ALMOBARAK ASSISTANT PROFESSOR

parts of the eye and eye disorders
Parts of the Eye and Eye Disorders

Parts of the Eye and Eye Disorders Pretest By: Colby Tharp Parts of the Eye

nourishment remove waste hyaluronic acid anterior chamber
nourishment + remove waste hyaluronic

Aqueous Humor Vitreous Humor Thin watery fluid Gel-like fluid Anterior

1
1 Last Revised August 2015 Luminance

Vision Lighting Ergonomics The right lighting for you! Light enters eye

quot quot amp
!"#$"%%& '()&

!"#$"%%& '()&

dementia falls
Dementia falls presentation Abby

Dementia falls presentation Abby Whiting Dementia Falls Nurse for Suffolk

theory of colour m easurem ent
Theory of colour m easurem ent Contem

Theory of colour m easurem ent Contem porary w ool dyeing and finishing Dr

receptors and effectors
RECEPTORS AND EFFECTORS ESTIMULI AND

RECEPTORS AND EFFECTORS ESTIMULI AND RESPONSES SENSORY RECEPTORS They are

dynamics of the vitreous humour induced by eye rotations
Dynamics of the vitreous humour induced

Dynamics of the vitreous humour induced by eye rotations: implications for

urban hydro sociology the mutual care between waters and
URBAN HYDRO-SOCIOLOGY: THE MUTUAL CARE

URBAN HYDRO-SOCIOLOGY: THE MUTUAL CARE BETWEEN WATERS AND CITIZENSHIP IN

1 queen s school of medicine
1. Queens School of Medicine 2.

Joseph Yang 1 , Nancy Chen 2 , Ian Silver 3 , Jonathan Butler 3 , Donatella

day 3 01 12 2018 time 10 00 am 12 00 noon venue tma pai
DAY 3: 01/12/2018, Time: 10.00 am

DAY 3: 01/12/2018, Time: 10.00 am 12.00 noon, Venue: TMA PAI HALL 1 Mode: